

Australian Clinical Labs Limited

ABN 94 645 711 128
Registered Office:
1868-1892 Dandenong Road
Clayton VIC 3168
Australia

clinicallabs.com.au

Monday, 16 February 2026

ACL 1H26 FINANCIAL RESULTS

The following announcements to the market are attached:

Appendix 4D

1H26 financial statements and statutory reports

- ✓ 1H26 financial results investor presentation

- ENDS -

This announcement was authorised for release to ASX by the Board of ACL. For further information regarding this announcement, please contact:

Investor Relations

Matthew Cordingley
Chief Financial Officer
Email: matthew.cordingley@clinicallabs.com.au
Phone: +61 (0) 409 287 681

Governance

Eleanor Padman
Company Secretary
Email: epadman@padmanadvisory.com.au
Phone: +61 (0) 422 002 918

Monday, 16 February 2026

IMPROVED EARNINGS QUALITY IN CHALLENGING MARKET CONDITIONS GROWTH IN EBIT, MARGINS AND EPS

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or the **Company**) is pleased to announce its results for the 6 months to 31 December 2025 (**1H26**), along with updates on FY26 Guidance, FY27 EBIT Initiatives, and employee payment matters.

AUD in millions	Actual 1H26	Actual 1H25	% Growth
Total Revenue	365.4	369.2	-1.0%
Underlying EBITDA ¹	94.7	95.1	-0.5%
Underlying EBIT ¹	28.0	27.3	2.4%
Underlying EBIT Margin ¹	7.7%	7.4%	30bps
Underlying NPAT ¹	13.2	12.1	8.9%
Statutory EBIT	19.7	26.9	-26.6%
Statutory NPAT	5.7	11.8	-51.7%
Free cash flow before interest, tax and financing ²	21.0	26.8	-21.4%
AUD in Cents per Share			
Underlying Earnings Per Share (EPS) ¹	6.7	6.0	12.8%

Highlights

- Revenue 1.0% down on the pcpc, primarily due to below average market growth and continued progress on optimising ACL's portfolio of commercial contracts and ACCs to be accretive to profit margins, which has seen a net reduction in ACCs compared to the pcpc. ACL was able to substantially offset the MBS fee cuts to B12 tests
- ACL's MBS outlays contracted 1.4%³ vs market growth of 1.8%⁴, delivering positive impact on earnings by focusing on profitable business. ACL's MBS outlays growth, adjusting for the closure of unprofitable ACCs, was up 1.3%³
- Underlying EBIT growth of 2.4% and margins expanded 30 bps to pcpc, driven by closure of loss-making ACCs, workforce productivity measures aligning labour to volumes, and technology and Ai-enabled productivity improvements in our laboratories
- Combination of the above-mentioned factors and initiatives, and lower depreciation, has contributed to an 8.9% growth in Underlying NPAT on the pcpc

1. Underlying results excludes certain non-recurring revenue and expenses
2. Free cash flow before interest, tax, financing excludes the one-off \$6.2m AIC settlement payment
3. ACL growth excluding non-Medicare commercial work adjusted for working days
4. Market data based on working-day adjusted Medicare statistics for National PEI volumes

- Underlying EPS of 6.7 cents per share (cps) is up 12.8% on improved profitability and return of capital to shareholders via the buyback
- Positive Free Cash Flow before interest, tax, and financing, but down on pcg due to softer revenues and modest negative working capital movement (expected to reverse in 2H26)
- Capital returns to shareholders equivalent to approximately 6% of current market capitalisation, comprising payment of FY25 final dividend and 3.6m shares bought back in 1H26. ACL will continue the buyback into the second half
- Interim fully franked interim dividend of 3.75 cps declared, up 0.25 cps on pcg

Chief Executive Officer and Executive Director, Melinda McGrath, said:

“The results presented today show improved underlying profitability, margins and EPS growth, which has been achieved in an environment of change in the industry, with many variables being managed concurrently.

Our ability to absorb the annual inflationary impacts on labour costs, where the Fair Work Commission increased wages under modern awards by 3.5% plus the 0.5% increase to superannuation on 1 July 2025, and the other broader inflationary pressures across our cost base and yet deliver earnings growth in a challenging market underscores the effectiveness of ACL’s strategic initiatives, flexible business design and operating leverage.

We have responded to the challenging external environment by optimising our ACC portfolio and focusing on contract management. Operationally, we have seen the positive impact of our AI and automation projects on the digitalisation of our billing practices and operational management, leveraging our unique competitive advantage of a single national laboratory information system.

The progress achieved this half provides a strong foundation for sustainable earnings growth into the future when volumes improve towards the long-term average. Continued focus on revenue-enhancing projects, efficiency, disciplined capital allocation and targeted growth in specialised diagnostics will remain central to our strategy.”

Interim dividend for 1H26

The ACL Board has declared an interim fully franked dividend of 3.75 cps, representing 55% of underlying NPAT.

The Record Date will be 13th March 2026 with a Payment Date of 31st March 2026.

FY26 Guidance

ACL is updating its FY26 guidance considering 1H26 financial performance and the outlook for the remainder of the financial year.

Revenue	\$735m - \$745m
Underlying EBIT	\$66m - \$69m
Gender Undervaluation impact	(\$1.8m)
Underlying EBIT (including Gender Undervaluation impact)	\$64m - \$67m

- Updated revenue guidance reflects the subdued pathology market in the 1H26 and expected market growth into the second half, taking into account the performance in January and February month-to-date
- As in previous years, there is an expected skew in profitability with H2 being stronger than H1. We expect to hold margins, with 2H26 margins at approximately 11%, bringing the full year margin to approximately 9%, before the impacts of gender undervaluation
- The estimated impact of gender undervaluation in FY26 (which was not included in the previously released FY26 guidance) relates to the first stage of wage increases for pathology collectors that commence on 1 April 2026. It comprises a \$1.2m increase in wages, plus a one-off non-recurring restatement to annual and long service leave provisions of \$0.6m

FY27 EBIT Initiatives

ACL has a strong pipeline of initiatives that support a positive outlook beyond FY26, with at least \$8m of EBIT expected in FY27. Various aspects of these initiatives are either now in place or being rolled out across H2. Key initiatives include:

- Workforce alignment to activity, continuing to improve the labour ratio
- Digitised non-Medicare billing, improving debtor performance and cash conversion
- Recovery of unfunded MBS tests commencing in H2, supported by new digitised billing processes
- AI driven optimisation of manual billing to reduce complexity and lift accuracy
- Pricing and rate reviews across non-Medicare items aligned to costs and market conditions
- Lab of the Future: state of the art automation and consolidation of the laboratory footprint
- AI initiatives delivering back-office savings and operating efficiencies

Fair Work Commission Decision (FWC) on Gender Undervaluation

The FWC has confirmed that there is gender-based undervaluation in the Health Professionals and Support Services Award 2020 (covering ACL's pathology collectors and health professionals), to be rectified by way of variation to the classifications and rates of pay in the Award.

The phasing in of the increases for pathology collectors is by way of an initial increase effective from 1 April 2026 with any remaining increase to take effect from 1 January 2027.

The proposed wage increases for other health professionals under the Award (excluding pathology collectors) will be phased in over five approximately equal annual stages, 12 months apart, commencing on 1 July 2026, with subsequent increases taking effect on 1 July each year until 2030.

ACL is committed to ensuring our employees are paid fairly. The size and scope of the wage increases in addition to routine annual increments are such that the industry needs support from the Government to avoid impacts on employment, patient access and billing, and regional services/collection centre numbers.

With our Industry body, Australian Pathology, ACL has been working collaboratively with the Department of Health, Disability and Aging to reach agreement with Government on an appropriate support package via investment in the Medicare Benefits Schedule.

With no government support, ACL plans to offset the increased wage costs through further closures or downsizing of collection centres and laboratories and take other mitigating steps as outlined in Australian Pathology's submission to the Fair Work Commission.

Australian Clinical Labs is currently in the process of assessing the full financial impact of the decision for FY27, including health professionals, and will update the market once this work is completed.

Historical Underpayments to ACL Employees

An internal review has identified that there have been underpayments in respect of discrete employee entitlements. ACL reviewed the period FY2017 to FY2025, which will result in back payments of approximately \$1.4m. ACL is in the process of remediating affected employees.

Consequently, ACL is investing resources to improve payroll processes and compliance.

ACL has engaged the Fair Work Ombudsman and the relevant unions and is keeping our employees informed, including contacting those directly affected.

Chief Executive Officer and Executive Director, Melinda McGrath, said:

"Ensuring our employees are paid correctly and in line with their awards and agreements is a fundamental priority. We sincerely apologise to our employees and have begun remediation for those affected".

A provision for the estimated \$1.4 million back payment was taken up as at 31 December 2025 and is included as a non-underlying expense in the 1H26 financial results.

Investor and Analyst Results Briefing

ACL Chief Executive Officer and Executive Director, Melinda McGrath, and Chief Financial Officer, Matthew Cordingley, will host a webcast for investors and analysts today at 12.30pm (Melbourne time).

Participants can register for the webcast by accessing this link:

https://clinicallabs-au.zoom.us/webinar/register/WN_D-a-zVHsRjKbdV4_MleFwQ

An archive of the briefing will be available afterwards at: <https://investors.clinicallabs.com.au/>

– ENDS –

This announcement was authorised for release to ASX by the Board of Directors of ACL. For further information regarding this announcement, please contact:

Matthew Cordingley
Chief Financial Officer
Email: Matthew.Cordingley@clinicallabs.com.au

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

Forward Looking Statements

This announcement may contain forward-looking statements which are statements that may be identified by words such as "may", "will", "would", "should", "could", "believes", "estimates", "expects", "intends", "plans", "anticipates", "predicts", "outlook", "forecasts", "guidance" and other similar words that involve risks and uncertainties. The FY26 forecast is an example of forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this announcement, are expected to take place. No person who has made any forward-looking statements in this announcement (including the Company) has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the directors and management of the Company. The Company cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

For personal use only



1H26 Results Presentation

Melinda McGrath, CEO and
Executive Director

Matthew Cordingley, CFO

16 February 2026

For personal use only



For personal use only



Contents

1H26 Result – Financial & Operational Highlights

1H26 Result – Financials

Industry Outlook & Growth Strategy

Outlook & Guidance

Appendix

Financial & Operational Highlights

Melinda McGrath
CEO & Executive Director



1H26 Result – Financial Highlights

EBIT growth and margin expansion on pcp after restructuring in low growth market

Revenue
\$365.4m
 -1.0% to pcp

Revenue growth moderated due to ACL continuing to optimise its portfolio of ACCs and commercial contracts to focus on margins. Market growth was lower than long term average, with ACL's MBS outlays contracting 1.4%¹ vs market growth of 1.8%². ACL's MBS outlays growth, adjusting for ACC closures, was 1.3%¹

EBIT³
\$28.0m
 7.7% margin

Underlying EBIT growth of 2.4% and margin expansion of 30 bps to pcp, driven by closure of loss-making ACCs, workforce productivity measures aligning labour to volumes, and technology and AI-enabled productivity improvements in our laboratories

NPAT³
\$13.2m
 +8.9% on pcp


Combination of the above-mentioned factors and initiatives, plus lower depreciation, has contributed to an **8.9% growth in Underlying NPAT** on the pcp. **Underlying EPS of 6.7cps up 12.8%** on increased profitability and impacts of buyback

FCF⁴
\$21.0m
 -\$5.8m on pcp

Positive Free Cash Flow before interest, tax, and financing, down on pcp due to softer revenues and modest negative working capital movement (expected to reverse in 2H26)

Capital Returns
\$27.8m
 in 1H26

Capital returns to shareholders equivalent to approximately 6% of current market capitalisation, comprising payment of FY25 final dividend and 3.6m shares bought back in 1H26. An **FY26 interim dividend** declared of **3.75cps, +0.25cps** on pcp. ACL will continue its buyback into the second half



1). ACL growth excluding non-Medicare commercial work adjusted for working days
 2). Market data based on working-day adjusted Medicare statistics for National PEI volumes

3). Underlying EBIT and NPAT excludes certain non-recurring revenue and expenses (for more information see slide 22)
 4). Free Cash Flow before interest, tax, financing excludes the one-off \$6.2m AIC settlement payment

1H26 Result – Revenue Bridge

Revenue outcomes driven by focus on disciplined growth at acceptable margins

1H25
Revenue

\$369.2m

Unprofitable ACC
reductions

(\$8.2m)

- Net reduction in unprofitable ACCs in this period – will only pursue growth at acceptable margins
- Revenue reduction was more than offset by rent, labour and consumables savings

Medicare Growth

\$3.7m

- Lower market MBS growth in 1H26 than long term average
- ACL's MBS growth, excluding the impacts of ACC closures, is 1.3%¹

Public hospitals /
commercial contracts

(\$1.4m)

- Like ACCs, ACL will not pursue commercial contracts at below acceptable margins
- Resulted in ACL not renewing certain contracts in this period

Net impact of B12 &
other fee cuts

(\$0.9m)

- ACL's initiatives almost completely offset the B12 cuts that commenced 1 July 25

Other growth

\$3.0m

- Revenue initiatives and growth across other businesses

1H26
Revenue

\$365.4m

- Overall Revenue declined 1% while EBIT grew 2.4% and NPAT grew 8.9%, validating ACL's long-term strategy for profitable growth
- ACL well placed for operating leverage release upon market growth returning to normal

1). ACL growth excluding non-Medicare commercial work adjusted for working days

1H26 Result – Operational Highlights

Focus on margins and profitable revenue growth to release operating leverage



For personal use only

ACL's Competitive Advantage

ACL is the only national pathology provider with a **single national Laboratory Information System (LIS)** (operating system) which reduces duplication, drives cost efficiencies, and enhances customer service - enables first to market bolt on technology

Improved Operating Efficiencies

Labour as a percentage of revenue continuing to perform at less than 44%

Lab operational efficiency (panels per FTE) rose 10.1% leveraging ACL's single national LIS

Logistics efficiency increased 13%, with route optimisation resulting in nearly 900,000 fewer kilometres travelled

Consumables as a percentage of revenue decreased 40bp to 17.4%

Leveraging Shared Services operations provides flexibility in resourcing and other variable costs

Patient NPS score of +79

Final testing of AI to enhance back-office functions, including manual data entry processes that will produce savings in 2026 and beyond

Revenue Growth Highlights

Rationalisation of our ACC network and Medicare cuts to vitamin B12, along with a sluggish GP consultation market has slowed GP growth YTD, however expecting increased GP Consult volumes due to impact of Bulk Bill incentive program

Positive specialist growth particularly in Out-Patient referrals (up 4% on pcp) with growth from our key specialties including Hematologist, Oncologists and Emergency Physicians

Commencement of e-Commerce & digitalisation to collect upfront payments, has seen an increase in non-MBS payments reducing the number of non-MBS debtors by up to 30%

Genetic Reproductive Health - Our Carrier Screening volume has been grown over 10% to pcp, ahead of market, along with improved growth in NIPT and other fertility testing

Increases in Oncology Genomic testing - ACL is the exclusive provider of Endopredict which helps to define the risk of breast cancer recurrence, the benefits of chemotherapy, and who can benefit from extended endocrine therapy. Since being introduced to the Medicare Schedule in 2024, has seen a 100% volume increase of these tests from Oncologist

ACL's Digital Journey

Our digital workflow from referral to result, and the software that gets us there



1. eRequest & eResults

eRequest now with 18% utilisation and integrated with all major clinic practice management software

Improves order accuracy and enhances patient convenience

eResults - over 39,000 referrers

Available on desktop & mobile app

Continuous new features added to enhance doctor experience



2. AI/OCR

- Solution devised using AI & OCR technology to automatically enter pathology request forms
- Over 50% of forms fit into current model
- Low volume testing course with rollout of phased trial planned March 26
- AI has the ability to read and interpret doctor handwriting
- ACL has active workflows of 250+ personnel supporting back-office functions




3. Click to Collect

- Route Optimisation software has been in use since 2019
- Since launch, route optimisation has provided 150,000km/mth benefit across group
- Futile stops have decreased by 50% with episodes per Km up 25%
- Software continues to improve route efficiency and labour effectiveness
- Click to collect usage now at 90% meaning better customer experience



4. Workforce


- Workforce planning via digital platform has been in use since 2018 predicts lowest cost roster for the skills required
- Version 5 has now been launched and provided an additional 6% benefit on FY24
- Since launch, platform has provided 23% labour efficiency across targeted areas
- Technology matches volume to labour and manages accordingly



ESG Highlights

Delivering strong performance across all areas of our ESG Mission

For personal use only



1). This calculated annually and is therefore the same disclosure as at 30 June 2025

Financials

Matthew Cordingley
CFO



1H26 Profit and Loss

Increased Underlying EBIT and NPAT in 1H26 (to pcg) despite challenging market

AUD in millions	Actual 1H26	Actual 1H25	% Growth
Total Revenue	365.4	369.2	-1.0%
Underlying EBITDA ¹	94.7	95.1	-0.5%
Underlying EBIT ¹	28.0	27.3	2.4%
Underlying EBIT Margin ¹	7.7%	7.4%	30bps
Underlying NPAT ¹	13.2	12.1	8.9%
Statutory EBIT	19.7	26.9	-26.6%
Statutory NPAT	5.7	11.8	-51.7%
Free cash flow before interest, tax and financing ²	21.0	26.8	-21.4%
AUD in Cents per Share			
Underlying Earnings Per Share (EPS) ¹	6.7	6.0	12.8%

Highlights

Revenue growth of -1.0% due to ACL continuing to optimise its portfolio of ACCs and commercial contracts and lower market growth

Underlying EBIT growth of +2.4% despite challenging market conditions. Closing unprofitable ACCs and technology enhancements and productivity initiatives more than absorbed inflation across our cost base

Underlying EBIT Margin of 7.7% up from 7.4% in 1H25, driven by closure of loss-making ACCs, workforce productivity measures aligning labour to volumes, and technology and AI-enabled productivity improvements in our laboratories

Underlying NPAT growth of +8.9% on the pcg and **Underlying EPS of 6.7cps up 12.8%**, driven by improved profitability and return of capital to shareholders via buyback


1). Underlying results excludes certain non-recurring revenue and expenses (for more information see slide 22)

2). Free cash flow before interest, tax and financing excludes AIC settlement of \$6.2m

1H26 Cash Flow

Positive operating cash flow and accretive capital management via buyback

AUD in millions	Actual 1H26	Actual 1H25	Actual 2H25	Actual CY25	Actual FY25
EBITDA¹	92.6	94.7	107.5	200.1	202.2
Non-cash items	1.0	1.9	1.7	2.7	3.6
Property related payments AASB 16	(67.8)	(67.3)	(68.8)	(136.6)	(136.1)
Cash EBITDA¹	25.8	29.3	40.4	66.2	69.7
Change in net working capital	(1.3)	1.5	8.0	6.7	9.5
Operating cash flow pre capex¹	24.5	30.8	48.4	72.9	79.2
Capital expenditure	(3.5)	(4.0)	(4.4)	(7.9)	(8.4)
Free cash flow before interest, tax and financing¹	21.0	26.8	44.0	65.0	70.8
Dividends paid	(17.8)	(18.0)	(6.9)	(24.7)	(24.9)
Borrowings	30.0	0.0	(13.0)	17.0	(13.0)
Share buy-back	(10.0)	(4.4)	(14.7)	(24.7)	(19.1)
Other financing and investing activities	0.1	-	(0.5)	(0.4)	(0.5)
Interest paid (excluding AASB 16 related interest)	(1.2)	(2.1)	(1.6)	(2.8)	(3.7)
Income tax paid	(15.0)	(7.8)	(6.6)	(21.6)	(14.4)
AIC settlement	(6.2)	-	-	(6.2)	-
Net cash flow	0.9	(5.5)	0.7	1.6	(4.8)
Net cash flow excluding AIC, financing and investing	4.8	16.9	35.8	40.6	52.7
Cash EBITDA to Operating cash flow	95.0%	105.3%	119.8%	110.0%	113.6%



Highlights

Free cash flow before interest, tax and financing of \$21.0m, (excludes the one-off AIC settlement of \$6.2m)

Robust Operating CF to Cash EBITDA of 95%, slightly down on pcp with a modest net working capital outflow, which is expected to reverse in 2H26

ACL returned \$27.8m to shareholders via dividends and buybacks in 1H26, equivalent to 6% of current market capitalisation

ACL's historical and ongoing **capital expenditure** requirements remain approximately **\$8m to \$10m per annum**

Income tax paid in 1H26 was higher due to an increase in assessed instalments compared to the prior period

1). Excludes AIC settlement of \$6.2m

1H26 Balance Sheet

Strong Balance Sheet underpins dividends and buyback

For personal use only

AUD in millions	Actual 1H26	Actual FY25
Cash and cash equivalents	22.4	21.4
Trade and other receivables	59.5	72.8
Inventories and other assets	33.5	25.8
Total current assets	115.5	120.1
Plant and equipment	34.0	36.9
Right-of-use assets	228.2	233.3
Intangible assets	165.1	165.2
Other assets and deferred tax assets	19.7	19.5
Total non-current assets	447.0	454.8
Total assets	562.5	574.8
Trade and other payables	(45.7)	(51.6)
Lease liabilities	(104.4)	(108.6)
Provisions	(46.4)	(47.2)
Deferred consideration, tax and other liabilities	(0.4)	(9.0)
Total current liabilities	(196.9)	(216.4)
Trade and other payables, provisions and deferred consideration	(3.8)	(4.7)
Lease liabilities	(138.5)	(139.8)
Borrowings	(72.2)	(42.0)
Total non-current liabilities	(214.5)	(186.5)
Total liabilities	(411.5)	(402.9)
Net Assets	151.0	172.0

Highlights

Stable cash position, \$22.4m

Net working capital stable, with a reduction in **accounts receivable** and **trade and other payables** due to December being a seasonally quieter trading month

Net Debt (excluding lease liabilities) of \$49.8m has increased during the half due to funding of the AIC settlement (\$6.2m), share buyback (\$10.0m) and FY25 final dividend payment (\$17.6m). ACL remains **conservatively leveraged** with a **strong balance sheet**

Banking facilities have a maturity of 31 July 2027 and ACL continues to remain comfortably within its covenants

Interim Dividend of 3.75cps for 1H26, which represents 55% of 1H26 Underlying NPAT. The final dividend for FY25, combined with the share buyback, represents a return to shareholders of \$27.8m in 1H26. Buyback to continue into H2

Interim Dividend **Record Date** of 13 March 2026 and **Payment Date** of 31 March 2026

Industry Outlook & Growth Strategy


Melinda McGrath
CEO & Executive Director




Industry Outlook

Pathology market growth is closing the gap; Green shoots with increase of GP Bulk billing incentive

Pathology Episodes (ex COVID-19 for FY20 – FY24¹)
#m, FY09 – FY26F



GP Attendances²
#m, FY09 – FY26F



Highlights

- Expansion of the tripled GP bulk-billing incentive (from Nov-25) is beginning to lift the Bulk Bill Rate, with GP attendances expected to rise over the next six months
- GP attendances excluding telehealth remain ~26% below historical trend, driven mainly by short consults
- Market volumes remain ~7.4% below historical trend, representing a significant recovery opportunity
- Catch-up of this shortfall implies a revenue opportunity of >\$46m for ACL

National GP Bulk Billing Snapshot³

National GP NRA Bulk Billing
Rate (Nov 25 - Jan 26)

81.4%
(4.5% increase)

No. of Practices changed from
Mixed Billing to Bulk Billing

1,269

1). Pathology Episodes sourced from Medicare statistics (Services Australia Statistics) with FY20 – FY24 data adjusted to exclude COVID-19 related pathology services

2). GP Attendances sourced from Medicare data (Service Australia Statistics). Data excludes Telehealth consults

3). National GP Bulk Billing Snapshot – 1 November 2025 to 31 January 2026

Growth Strategy

Clear opportunity pipeline to drive increased shareholder returns

Disciplined network expansion

Sustainable and profitable network expansion and hospital services growth

Complementary non-Medicare additions to network including Clinical Trials and Skin Cancer Clinics

High value specialist inpatient and outpatient services

Strategic New Business

Enhanced focus on Commercial pathology

Research program partnerships

New high volume test development

JVs to develop new markets

Specialist genetics testing

Exclusive commercialisation of recently accredited tests for Melanoma

Strategic Acquisitions

AU pathology acquisitions

SunDoctors GP practice growth via acquisition pipeline

International and adjacent opportunities

Other strategic investments aligned to competitive advantage

Revenue Initiatives

Digitised non-Medicare billing, improving debtors and cash conversion

Unfunded MBS test recovery to begin in H2 with stronger processes

Indexation now applied to one-third of the MBS; advocacy continues

AI-driven optimisation of manual billing to reduce complexity and lift accuracy

Regular pricing and rate reviews across non-Medicare items aligned to costs and market conditions

Operational Improvement & Restructuring

Lab of the Future implementation in progress

National Skin Laboratory to leverage ACL exposure to this segment – better service, improved productivity, greater returns

AI / Automation of operations

AI / Automation of diagnostics / clinical practice

Lab of the Future

Leveraging ACL's Competitive Advantage - National Laboratory Information System

For personal use only



Efficiency
Gain

- Over 50% of routine work to be processed in a highly automated 24/7 laboratory
- Overall efficiency of ACL national laboratories will increase by over 20%



Faster Critical
TAT

- Turn around times for critical tests from GPs will improve by 30% by implemented priority testing protocols



Robotics
Infrastructure

- AI, machine learning and robotics will significantly improve sample handling and performance



Rollout Schedule

- Progressive rollout through FY27/28

National Skin Cancer Business

Leveraging ACL's National LIS & boutique skin cancer business (SunDoctors)



State-of-the-Art
Automated
Skin Lab

Creating a high-throughput, precision processing



Cancer
Expertise
Integration

Combining the clinical and operational experience of our SunDoctors, Southern Sun and ACL businesses



Specialists
Workforce

Dedicated dermatopathologists and training programs



Industry
leading
TAT's

Combining our streamlined workflows, clinical and operational experience to providing results back to referrers and their patients quicker to achieve better patient outcomes



Cost
Reduction

Cost per case reduced by 20% with efficiency in processing and diagnosis



Underpinned by Our SunDoctors Business

Strong acquisition pipeline of Skin Cancer Medical Centres

New CEO – experienced in clinic acquisitions and integrations

Increase consulting utilisation by expanding room capacity and targeting patient acquisition

AI opportunities to enhance workflows, support clinical service delivery

Increasing non-Medicare opportunities via complementary skin services

Outlook & Guidance

Melinda McGrath
CEO & Executive Director

AUSTRALIAN
Clinicalabs



Gender Undervaluation Impacts

Fair Work Commission (FWC) Decision

Decision Summary

- The FWC has confirmed that there is gender-based undervaluation in the Health Professionals and Support Services Award 2020 (covering ACL's pathology collectors and health professionals), to be rectified by way of variation to the classifications and rates of pay in the Award
- The phasing in of the increases for **pathology collectors** is by way of an initial increase effective from 1 April 2026 with any remaining increase to take effect from 1 January 2027
- The proposed wage increases for other **health professionals** will be phased in over five approximately equal annual stages, 12 months apart, commencing on 1 July 2026, with subsequent increases taking effect on 1 July each year until 2030

ACL Impacts and Response

- ACL is committed to ensuring our employees are paid fairly. The size and scope of the wage increases in addition to routine annual increments are such that the industry needs support from the Government to avoid impacts on employment, patient access and billing and regional services/collection centre numbers
- ACL estimates the impact of the increase in wage rates to pathology collectors is approximately \$1.2m in FY26. There is also a one-off and non-recurring restatement of annual and long service leave provision of \$0.6m
- The impacts for FY27 will include a full year of pathology collector increases and the first of five increases for health professionals. ACL is in the process of estimating this impact for FY27 and will make this known once this work is complete
- With our Industry body – Australian Pathology – ACL has been working collaboratively with the Department of Health, Disability and Aging to reach agreement with Government on an appropriate support package via investment in the Medicare Benefits Schedule
- With no government support, ACL plans to offset the increased wage costs through further closures or downsizing of collection centres and laboratories and take other mitigating steps as outlined in Australian Pathology's submission to the Fair Work Commission

Updated FY26 Guidance & FY27 Initiatives

FY26 Guidance¹

ACL is updating its FY26 guidance considering 1H26 financial performance and the outlook for the remainder of the financial year

Revenue	\$735m - \$745m
Underlying EBIT	\$66m - \$69m
Gender Undervaluation impact	(\$1.8m)
Underlying EBIT (including Gender Undervaluation impact)	\$64m - \$67m

- Updated revenue guidance reflects the subdued pathology market in the 1H26 and expected market growth into the second half, taking into account the performance in January and February month-to-date
- As in previous years, there is an expected skew in profitability with H2 being stronger than H1. We expect to hold margins, with 2H26 margins at approximately 11%, bringing the full year margin to approximately 9%, before the impacts of gender undervaluation
- The estimated impact of gender undervaluation in FY26 (which was not included in the previously released FY26 guidance) relates to the first stage of wage increases for pathology collectors that commence on 1 April 2026. It comprises a \$1.2m increase in wages, plus a one-off non-recurring restatement to annual and long service leave provisions of \$0.6m

FY27 EBIT Initiatives

ACL has a **strong pipeline of initiatives** that support a positive outlook beyond FY26, with **at least \$8m of EBIT expected in FY27**. Various aspects of these initiatives are either now in place or being rolled out across H2. Key initiatives include:

- **Digitised non-Medicare billing**, improving debtor performance and cash conversion
- **Recovery of unfunded MBS tests** commencing in H2, supported by new digitised billing processes
- **AI driven optimisation of manual billing** to reduce complexity and lift accuracy
- **Pricing and rate reviews** across non-Medicare items aligned to costs and market conditions
- **Lab of the Future**: state of the art automation and consolidation of the laboratory footprint
- **AI initiatives delivering back-office savings** and operating efficiencies
- **Workforce alignment to activity**, continuing to improve the labour ratio

1). H1/H2 seasonality in earnings is expected to be like that achieved in FY25

Appendix

Reconciliations

Reported & Underlying EBITDA, EBIT and NPAT

AUD in millions	Statutory 1H26	AIC Settlement	Labour - Prior periods	Other	Underlying 1H26
Total Revenue	365.4	-	-	-	365.4
EBITDA	86.4	6.2	1.4	0.6	94.7
EBIT	19.7	6.2	1.4	0.6	28.0
<i>EBIT margin</i>	5.4%				7.7%
NPAT	5.7	6.1	1.0	0.4	13.2
EBITDA (pre-AASB 16)	19.3	6.2	1.4	0.6	27.6
<i>EBITDA (pre-AASB 16) margin</i>	5.3%				7.5%

**AIC
settlement,
prior period
labour and
legal fees**

Adjustments between reported and underlying reflect:

- A settlement was reached between ACL and the Australian Information Commissioner (AIC) to resolve the civil penalty proceeding commenced in the Federal Court in November 2023 relating to a cyberattack on the Medlab Pathology business acquired by ACL. Under the orders ACL paid aggregate civil penalties of \$5.8m and made a contribution of \$0.4m to the AIC's legal costs
- 'Labour - Prior periods' relates to historical employee underpayments from FY17 to FY25 that were provisioned at 31 December
- 'Other' includes ACL legal fees predominately relating to defending civil proceedings with the AIC (noted above) and some redundancy costs. These costs have been partially offset by a historical GST claim within other income

Reconciliations

AASB 16 to pre-AASB 16

AUD in millions	Actual 1H26	Actual 1H25	Actual 2H25	Actual CY25	Actual FY25
Statutory EBITDA (AASB 16)	86.4	94.7	107.5	193.9	202.2
Less: Operating lease rentals (pre-AASB 16)	(67.1)	(66.9)	(68.3)	(135.4)	(135.2)
EBITDA (pre-AASB 16)	19.3	27.8	39.2	58.5	67.0
Statutory EBIT (AASB 16)	19.7	26.9	39.2	58.9	66.1
Add: Depreciation of Right-of-Use asset (AASB 16)	60.3	61.0	61.7	122.0	122.7
Less: Operating lease rentals (pre-AASB 16)	(67.1)	(66.9)	(68.3)	(135.4)	(135.2)
EBIT (pre-AASB 16)	12.9	21.0	32.6	45.5	53.6
Statutory NPAT (AASB 16)	5.7	11.8	21.0	26.7	32.8
Add: Depreciation of Right-of-Use asset (AASB 16)	60.3	61.0	61.7	122.0	122.7
Add: Interest expense on lease liabilities	7.1	7.2	7.1	14.3	14.3
Less: Operating lease rentals (pre-AASB 16)	(67.1)	(66.9)	(68.3)	(135.4)	(135.2)
Pre tax Impact NPAT (pre-AASB 16)	5.9	13.1	21.5	27.4	34.6
Income tax impact	(0.1)	(0.4)	(0.1)	(0.2)	(0.5)
NPAT (pre-AASB 16)	5.9	12.7	21.4	27.3	34.1
<i>EBITDA margin AASB 16</i>	23.6%	25.6%	28.9%	26.3%	27.3%
<i>EBITDA margin (pre-AASB 16)</i>	5.3%	7.5%	10.5%	7.9%	9.0%
<i>EBIT margin AASB 16</i>	5.4%	7.3%	10.5%	8.0%	8.9%
<i>EBIT margin (pre-AASB 16)</i>	3.5%	5.7%	8.8%	6.2%	7.2%

Important notice and disclaimer



Summary information

This Presentation contains summary information about Australian Clinical Labs Limited (ACN 645 711 128) (ACL) and its activities which is current only as at the date of this Presentation (unless specified otherwise). The material in this Presentation is general background information and does not purport to be complete. It does not purport to summarise all information that an investor should consider when making an investment decision. It should be read in conjunction with ACL's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au.

No representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this Presentation. To the maximum extent permitted by law, ACL, its related bodies corporate and their respective directors, officers, employees, agents and advisers disclaim all liability and responsibility for any direct or indirect loss, costs or damage which may be suffered by any recipient through use of or reliance on anything contained in, implied by or omitted from this Presentation. Reliance should not be placed on information or opinions contained in this Presentation and, subject only to any legal obligation to do so, ACL does not have any obligation to correct or update the content of this Presentation. The information in this Presentation remains subject to change without notice.

Financial information

Certain financial measures included in this Presentation are 'non-IFRS financial information' under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and also 'non-GAAP financial measures' within the meaning of Regulation G under the U.S. Securities Act and are not recognised under AAS and International Financial Reporting Standards (IFRS). Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Although ACL believes these non-IFRS financial measures provide useful information to investors in measuring the financial performance and condition of its business, investors are cautioned not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this Presentation.

Certain figures, amounts, percentages, estimates, calculations of value and fractions provided in

this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation. All financial information in this Presentation is in Australian dollars (\$) or A\$) unless otherwise stated.

Forward-looking information

This Presentation and any related materials and cross-referenced information contain forward-looking statements, which may be identified by the use of terminology including 'may', 'will', 'would', 'could', 'should', 'expects', 'believes', 'targets', 'likely', 'plans', 'intends', 'aims', 'anticipates', 'estimates', 'continue', 'objectives', 'forecasts', 'guidance', 'outlook' or similar expressions. Indicators of, and guidance on, future earnings and financial position are also forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this Presentation, are expected to take place. These forward-looking statements are not guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of ACL or any of its related entities, and which may cause actual results to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. Readers are cautioned not to place undue reliance on forward-looking statements.

Past performance

The past performance and position of ACL reflected in this Presentation is given for illustrative purposes only. Past performance of ACL cannot be relied upon as an indicator of (and provides no guidance as to) the future performance or condition of ACL, including future share price performance.

No offer of securities

Nothing in this Presentation should be construed as either an offer or a solicitation of an offer to buy or sell ACL securities. Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the financial situation, investment objectives or needs of any particular investor. Before making any investment or other decision, investors should consider these factors, and consult with their own legal, tax, business and/or financial advisors.

Thank You

Contact

Matthew Cordingley, Chief Financial Officer
Matthew.Cordingley@clinicalabs.com.au